title: The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy.
abstract: Advances in chemotherapy for acute myeloid leukemia (AML) have resulted in the exclusion of patients not undergoing induction chemotherapy from research studies. To examine in detail the clinical experience of such patients, we retrospectively analyzed the outcomes of consecutive patients diagnosed with AML at our hospital from 2004 to 2012. Of 158 AML patients, 43 (27 %) did not undergo induction chemotherapy. Their median survival duration was 1.5 months, with 11, six, and four patients surviving more than 3, 6, and 12 months, respectively. As expected, their survival was worse than that of those treated with intensive or less-intensive induction therapy (14, 74, and 47 % at 1 year, and 0, 40, and 10 % at 4 years, respectively). Low white blood cell count at AML diagnosis and prior history of myelodysplastic syndrome were significantly associated with longer survival. Our findings suggest that modern supportive care measures do not prolong survival for AML patients not undergoing induction chemotherapy, although certain patients show relatively long survival. These data should prove helpful in discussing treatment pathways with patients for cases in which palliative or supportive therapy alone may be a viable treatment option.
authors.affiliation: Department of Hematology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan, myanada@fujita-hu.ac.jp.
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Yanada
authors.forename: Akinao
authors.initials: A
authors.lastname: Okamoto
authors.forename: Yoko
authors.initials: Y
authors.lastname: Inaguma
authors.forename: Masutaka
authors.initials: M
authors.lastname: Tokuda
authors.forename: Satoko
authors.initials: S
authors.lastname: Morishima
authors.forename: Tadaharu
authors.initials: T
authors.lastname: Kanie
authors.forename: Yukiya
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Shuichi
authors.initials: S
authors.lastname: Mizuta
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Akatsuka
authors.forename: Masataka
authors.initials: M
authors.lastname: Okamoto
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Emi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002423:Cause of Death; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
references.citation: Int J Hematol. 2014 Aug;100(2):141-51
references.pmid: 24996615
references.citation: J Clin Oncol. 1989 Sep;7(9):1268-74
references.pmid: 2475589
references.citation: Haematologica. 2012 Dec;97(12):1916-24
references.pmid: 22773600
references.citation: J Chronic Dis. 1961 Dec;14:593-608
references.pmid: 13894982
references.citation: Blood. 2009 Jul 30;114(5):937-51
references.pmid: 19357394
references.citation: Cancer Chemother Rep. 1973 Nov-Dec;57(4):485-8
references.pmid: 4586956
references.citation: Blood. 2010 Jan 21;115(3):453-74
references.pmid: 19880497
references.citation: Blood. 2010 Jul 22;116(3):354-65
references.pmid: 20385793
references.citation: Ann N Y Acad Sci. 1954 Dec 6;60(2):322-58
references.pmid: 14350538
references.citation: J Clin Oncol. 2014 Nov 1;32(31):3463-9
references.pmid: 25185093
references.citation: Cancer. 2007 Mar 15;109(6):1114-24
references.pmid: 17315155
references.citation: Blood. 2009 Apr 30;113(18):4179-87
references.pmid: 19008455
references.citation: Int J Hematol. 2012 Sep;96(3):342-9
references.pmid: 22825970
references.citation: Blood. 2007 Mar 1;109(5):1810-6
references.pmid: 17095617